Fortress Biotech (NASDAQ:FBIOP – Get Free Report) is expected to post its results before the market opens on Monday, November 16th. Analysts expect Fortress Biotech to post earnings of ($0.27) per share and revenue of $21.57 million for the quarter.
Fortress Biotech Stock Performance
Shares of NASDAQ FBIOP opened at $14.84 on Monday. The business’s 50 day moving average price is $17.11 and its 200-day moving average price is $16.29. Fortress Biotech has a fifty-two week low of $6.27 and a fifty-two week high of $21.43.
About Fortress Biotech
Fortress Biotech, Inc is a U.S.-based biopharmaceutical company that acquires, develops and commercializes prescription medicines. Its work spans areas including oncology, rare diseases, dermatology and other specialty markets.
The company operates through a network of subsidiary businesses and uses partnerships and licensing arrangements to advance drug candidates and bring therapies to market. Its portfolio includes both development-stage programs and commercial products, with activities conducted primarily in the United States.
Fortress was founded in 2006 as Coronado Biosciences and adopted its current name in 2015.
See Also
- Five stocks we like better than Fortress Biotech
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
- After the Midterms, Which of These 3 Defense ETFs Looks Strongest?
- The Ugly Truth Behind SoundHound’s Q3 Results
Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
-american-depositary-shares-logo-1200x675.png){kind=logo}
